MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-89-899270
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$71.16 million
Profitability
Miscellaneous
Employees329
Next Earnings Date3/18/2020 (Estimated)
OptionableNot Optionable
MorphoSys (ETR:MOR) Frequently Asked Questions
What is MorphoSys' stock symbol?
MorphoSys trades on the ETR under the ticker symbol "MOR."
When is MorphoSys' next earnings date?
What price target have analysts set for MOR?
7 equities research analysts have issued 12-month target prices for MorphoSys' shares. Their forecasts range from €81.00 to €150.00. On average, they anticipate MorphoSys' share price to reach €126.29 in the next year. This suggests a possible upside of 6.3% from the stock's current price. View Analyst Price Targets for MorphoSys.
What is the consensus analysts' recommendation for MorphoSys?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys.
Has MorphoSys been receiving favorable news coverage?
Media coverage about MOR stock has trended very negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MorphoSys earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the stock's share price in the near future. View News Stories for MorphoSys.
Who are some of MorphoSys' key competitors?
Some companies that are related to MorphoSys include Cronos Group (CRON), BTG (BTG), Abcam (ABC), Kodiak Sciences (KOD), Genus (GNS), Polynovo (PNV), Vir Biotechnology (VIR), Mesoblast (MSB), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Immutep (IMM), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Cel-Sci (CVM) and Oxford BioMedica (OXB).
What other stocks do shareholders of MorphoSys own?
Who are MorphoSys' key executives?
MorphoSys' management team includes the folowing people:
- Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
- Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
- Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
- Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
- Mr. Klaus De Wall, Head of Accounting & Tax
What is MorphoSys' stock price today?
One share of MOR stock can currently be purchased for approximately €118.80.
How big of a company is MorphoSys?
What is MorphoSys' official website?
How can I contact MorphoSys?
MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.
MarketBeat Community Rating for MorphoSys (ETR MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
